Payment overview · 2025
General Payments
$24,997.39
154 reported records · 25 companies
Healthcare provider profile · identity verified
Gregory Breen, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · WOODBURY, NJ · NPI 1538119961
Verified facts
What the public records show
CMS Open Payments records show Gregory Breen, M.D. received $24,997.39 in general payments during 2025 across 154 reported records.
Lilly USA, LLC accounted for 85.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 33 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Nucala, Sunosi, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BEVESPI AEROSPHERE as an associated drug or biological on 763 records involving 473 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Bevespi Aerosphere by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Symbicort by this doctor in 2024.
Axsome Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Sunosi as an associated drug or biological on 19758 records involving 6305 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Sunosi by this doctor in 2024.
Azurity Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported HORIZANT as an associated drug or biological on 2733 records involving 1696 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Horizant by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUCALA as an associated drug or biological on 100127 records involving 16970 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Nucala by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 793 claims for Trelegy Ellipta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 127 claims for Eliquis by this doctor in 2024.
Vifor Pharma, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Zemaira as an associated drug or biological on 1409 records involving 818 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Zemaira by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $21,448.45 | 85.8% | 28 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $1,450.26 | 5.8% | 5 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $427.50 | 1.7% | 33 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $299.54 | 1.2% | 12 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $268.76 | 1.1% | 16 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $160.00 | 0.6% | 12 | 2025 |
| Pulmonx Corporation | Unresolved — no canonical attribution shown | $104.49 | 0.4% | 4 | 2025 |
| HARMONY BIOSCIENCES LLC | Unresolved — no canonical attribution shown | $81.52 | 0.3% | 5 | 2025 |
| Avadel CNS Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $75.96 | 0.3% | 4 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $70.04 | 0.3% | 4 | 2025 |
| United Therapeutics Corporation | Unresolved — no canonical attribution shown | $69.47 | 0.3% | 4 | 2025 |
| Invivyd Inc | Unresolved — no canonical attribution shown | $68.18 | 0.3% | 3 | 2025 |
| ZOLL Respicardia, Inc. | Unresolved — no canonical attribution shown | $62.80 | 0.2% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $61.62 | 0.2% | 4 | 2025 |
| Grifols USA, LLC | Unresolved — no canonical attribution shown | $57.28 | 0.2% | 3 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $52.54 | 0.2% | 2 | 2025 |
| Insmed, Inc. | Unresolved — no canonical attribution shown | $50.33 | 0.2% | 3 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $44.47 | 0.2% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $34.82 | 0.1% | 2 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $31.74 | 0.1% | 1 | 2025 |
| Vifor Pharma, Inc. | Unresolved — no canonical attribution shown | $16.43 | 0.1% | 1 | 2025 |
| JAZZ PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $15.98 | 0.1% | 1 | 2025 |
| Azurity Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.59 | 0.1% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $15.45 | 0.1% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $14.17 | 0.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $21,150.00 | 15 |
| Food and Beverage | $2,447.39 | 137 |
| Consulting Fee | $1,400.00 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $21,448.45 | 28 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $1,450.26 | 5 | 2025 |
Source payment records
|
|||||
| DUPIXENT Normalized: dupixent |
Biological | GENZYME CORPORATION, Regeneron Healthcare Solutions, Inc. | $428.76 | 28 | 2025 |
Source payment records
|
|||||
| NUCALA Normalized: nucala |
Biological | GlaxoSmithKline, LLC. | $297.82 | 19 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $217.33 | 7 | 2025 |
Source payment records
|
|||||
| TEZSPIRE Normalized: tezspire |
Biological | Amgen Inc., AstraZeneca Pharmaceuticals LP | $181.20 | 4 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $144.76 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $129.68 | 14 | 2025 |
Source payment records
|
|||||
| CHARTIS CATHETER Normalized: chartis catheter |
Device | Pulmonx Corporation | $104.49 | 4 | 2025 |
Source payment records
|
|||||
| PULMONX CHARTIS TABLET CONSOLE Normalized: pulmonx chartis tablet console |
Device | Pulmonx Corporation | $104.49 | 4 | 2025 |
Source payment records
|
|||||
| ZEPHYR DELIVERY CATHETER Normalized: zephyr delivery catheter |
Device | Pulmonx Corporation | $104.49 | 4 | 2025 |
Source payment records
|
|||||
| ZEPHYR ENDOBRONCHIAL VALVE Normalized: zephyr endobronchial valve |
Device | Pulmonx Corporation | $104.49 | 4 | 2025 |
Source payment records
|
|||||
| WAKIX Normalized: wakix |
Drug | HARMONY BIOSCIENCES LLC | $81.52 | 5 | 2025 |
Source payment records
|
|||||
| LUMRYZ Normalized: lumryz |
Drug | Avadel CNS Pharmaceuticals, LLC | $75.96 | 4 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $70.04 | 4 | 2025 |
Source payment records
|
|||||
| Tyvaso Normalized: tyvaso |
Drug | United Therapeutics Corporation | $69.47 | 4 | 2025 |
Source payment records
|
|||||
| PEMGARDA Normalized: pemgarda |
Biological | Invivyd Inc | $68.18 | 3 | 2025 |
Source payment records
|
|||||
| remede System Normalized: remede system |
Device | ZOLL Respicardia, Inc. | $62.80 | 2 | 2025 |
Source payment records
|
|||||
| Sunosi Normalized: sunosi |
Drug | Axsome Therapeutics, Inc. | $61.62 | 4 | 2025 |
Source payment records
|
|||||
| Prolastin-C Liquid Normalized: prolastin c liquid |
Biological | Grifols USA, LLC | $57.28 | 3 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $52.68 | 3 | 2025 |
Source payment records
|
|||||
| Vest Therapy Und Normalized: vest therapy und |
Device | Philips North America LLC | $52.54 | 2 | 2025 |
Source payment records
|
|||||
| Arikayce Normalized: arikayce |
Drug | Insmed, Inc. | $50.33 | 3 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $50.26 | 3 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $50.26 | 3 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $44.47 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $34.82 | 2 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $31.74 | 1 | 2025 |
Source payment records
|
|||||
| Veltassa Normalized: veltassa |
Drug | Vifor Pharma, Inc. | $16.43 | 1 | 2025 |
Source payment records
|
|||||
| XYWAV Normalized: xywav |
Drug | JAZZ PHARMACEUTICALS INC. | $15.98 | 1 | 2025 |
Source payment records
|
|||||
| ALVESCO Normalized: alvesco |
Drug | Azurity Pharmaceuticals, Inc. | $15.59 | 1 | 2025 |
Source payment records
|
|||||
| Adempas Normalized: adempas |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $14.17 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $8.08 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| NUCALA nucala |
2025 | Nucala | 2024 | 66 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Sunosi sunosi |
2025 | Sunosi | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 793 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BEVESPI AEROSPHERE open payments reported associated product |
CMS Open Payments — General Payments 763 supporting records · 473 recipient NPIs · example record 1206131384 |
Bevespi Aerosphere · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
54 | 20 |
| Axsome Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | Sunosi open payments reported associated product |
CMS Open Payments — General Payments 19758 supporting records · 6305 recipient NPIs · example record 1235293059 |
Sunosi · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Azurity Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | HORIZANT open payments reported associated product |
CMS Open Payments — General Payments 2733 supporting records · 1696 recipient NPIs · example record 1242666828 |
Horizant · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | NUCALA open payments reported associated product |
CMS Open Payments — General Payments 100127 supporting records · 16970 recipient NPIs · example record 1190332378 |
Nucala · 2024 Exact normalized brand match · 1 Part D row |
66 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
793 | 179 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
127 | 20 |
| Vifor Pharma, Inc. Exact reporting entity; no affiliate inference |
2025 | Zemaira open payments reported associated product |
CMS Open Payments — General Payments 1409 supporting records · 818 recipient NPIs · example record 1172020727 |
Zemaira · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 793 | 179 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 566 | 204 |
| Montelukast Sodium | Montelukast Sodium | 385 | 114 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 381 | 110 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 250 | 57 |
| Breo Ellipta | Fluticasone/Vilanterol | 239 | 59 |
| Prednisone | Prednisone | 173 | 46 |
| Fluticasone Propionate | Fluticasone Propionate | 161 | 65 |
| Eliquis | Apixaban | 127 | 20 |
| Incruse Ellipta | Umeclidinium Bromide | 120 | 25 |
| Spiriva Respimat | Tiotropium Bromide | 117 | 28 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 116 | 31 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 101 | 26 |
| Armodafinil | Armodafinil | 97 | 20 |
| Ventolin Hfa | Albuterol Sulfate | 88 | 36 |
| Azelastine Hcl | Azelastine Hcl | 77 | 25 |
| Nucala | Mepolizumab | 66 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 58 | 19 |
| Symbicort | Budesonide/Formoterol Fumarate | 54 | 20 |
| Arnuity Ellipta | Fluticasone Furoate | 53 | 14 |
| Azithromycin | Azithromycin | 52 | 16 |
| Varenicline Tartrate | Varenicline Tartrate | 47 | 20 |
| Ofev | Nintedanib Esylate | 44 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 44 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 39 | 36 |
| Xarelto | Rivaroxaban | 37 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 35 | 14 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 34 | suppressed |
| Fasenra Pen | Benralizumab | 31 | suppressed |
| Levalbuterol Tartrate Hfa | Levalbuterol Tartrate | 31 | 13 |
| Dupixent Syringe | Dupilumab | 29 | suppressed |
| Modafinil | Modafinil | 28 | suppressed |
| Xolair | Omalizumab | 26 | suppressed |
| Bevespi Aerosphere | Glycopyrrolate/Formoterol Fum | 25 | suppressed |
| Sunosi | Solriamfetol Hcl | 25 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 23 | suppressed |
| Dulera | Mometasone/Formoterol | 22 | suppressed |
| Fluticasone-Vilanterol | Fluticasone/Vilanterol | 22 | suppressed |
| Roflumilast | Roflumilast | 22 | suppressed |
| Tiotropium Bromide | Tiotropium Bromide | 21 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 20 | 17 |
| Clonazepam | Clonazepam | 19 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 18 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 18 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 18 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Methylprednisolone | Methylprednisolone | 17 | 17 |
| Pirfenidone | Pirfenidone | 17 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Asmanex Hfa | Mometasone Furoate | 16 | suppressed |
| Aralast Np | Alpha-1-Proteinase Inhibitor | 14 | suppressed |
| Dupixent Pen | Dupilumab | 14 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 14 | suppressed |
| Gabapentin | Gabapentin | 13 | suppressed |
| Prolastin C | Alpha-1-Proteinase Inhibitor | 13 | suppressed |
| Alprazolam | Alprazolam | 12 | suppressed |
| Azelastine-Fluticasone | Azelastine/Fluticasone | 12 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 12 | suppressed |
| Mycophenolic Acid | Mycophenolate Sodium | 12 | suppressed |
| Zemaira | Alpha-1-Proteinase Inhibitor | 12 | suppressed |
| Bosentan | Bosentan | 11 | suppressed |
| Furosemide | Furosemide | 11 | suppressed |
| Horizant | Gabapentin Enacarbil | 11 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $24,997.39 · 154 records | Lilly USA, LLC | ABRYSVO, AIRSUPRA, ALVESCO, AREXVY, Adempas, Arikayce, BREZTRI, CHARTIS CATHETER, COMIRNATY, DUPIXENT, INSPIRE, LUMRYZ, MOUNJARO, NUCALA, PEMGARDA, PREVNAR 20, PULMONX CHARTIS TABLET CONSOLE, PURIFIED CORTROPHIN GEL, Prolastin-C Liquid, Sunosi, TEZSPIRE, TRELEGY ELLIPTA, Tyvaso, Veltassa, Vest Therapy Und, WAKIX, Wegovy, XYWAV, YUPELRI, ZEPBOUND, ZEPHYR DELIVERY CATHETER, ZEPHYR ENDOBRONCHIAL VALVE, remede System | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Nucala play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error